Search Results

Cover Focus

Diversity in Ophthalmology

Examining the state of diversity in ophthalmology and how to build a more inclusive field.

Leon W. Herndon, MD; Constance Okeke, MD, MSCE; Gloria P. Fleming, MD; Mildred M.G. Olivier, MD; Zaiba Malik, MD; and Eve Higginbotham, SM, MD, ML

Focus On Diversity And Inclusion

Promoting Diversity

The National Medical Association works to reduce racial and ethnic disparities in medicine.

Mildred M. G. Olivier, MD

Research Results

The Word of the Day in Health Care: Accountability

Ophthalmologists have an opportunity to advance health care.

Eve J. Higginbotham, SM, MD

Clinical Strategies

Glaucoma Screenings and Treatment Under Siege

When will the evidence be enough?

Eve J. Higginbotham, SM, MD

Current Options for Cyclophotocoagulation

An overview of transscleral diode photocoagulation and endocyclophotocoagulation.

Mildred M. G. Olivier, MD

Therapeutics Update

Improving Compliance

Glaucoma Today asked four physicians to share their top tips for increasing patients' adherence to prescribed glaucoma therapy.

Eve J. Higginbotham, MD; George L. Spaeth, MD; David S. Friedman, MD, MPH, PhD; and Michele C. Lim, MD

Point/Counterpoint: Does Glaucoma Medications' BAK Content Make a Difference in Clinical Practice?

Yes, it matters.

Robert J. Noecker, MD, MBA

Point/Counterpoint: Does Glaucoma Medications' BAK Content Make a Difference in Clinical Practice?

Yes, it matters.

Robert J. Noecker, MD, MBA

Conflict of Interest

Academics weigh in on the controversy.

Gillian McDermott, Editor-in-Chief

Conflict of Interest

Academics weigh in on the controversy.

Gillian McDermott, Editor-in-Chief

Debate: Does Race Matter in Glaucoma?

Viewpoint No. 2: This factor is mutable and therefore not important.

Eve J. Higginbotham, MD

Would You Treat These Patients?

Eydie G. Miller, MD, rises to the challenge of determining whether and how to treat two glaucoma suspects.

Eve J. Higginbotham, MD

Would You Treat These Patients?

Eydie G. Miller, MD, rises to the challenge of determining whether and how to treat two glaucoma suspects.

Eve J. Higginbotham, MD

The Impact of a Prostaglandin's First-Line Approval

Glaucoma subspecialists comment on how XALATAN's FDA approval as a first-line treatment affects clinical practice.

ROBERT J. NOECKER, MD; PHILIP P. CHEN, MD; ROBERT D. FECHTNER, MD; AND EVE J. HIGGINBOTHAM, MD